Targets › CD38
14 programs from 14 companies in 315 trials: 164 Phase 2, 62 Phase 1, 55 Phase 3, 34 Phase 4; Oncology, Hematology, Other; next expected readout Nov 2026.
Multifunctional transmembrane glycoprotein able to exert enzymatic activities and also to mobilize calcium, to transduce signals, to adhere to hyaluronan and to other ligands. Synthesizes cyclic ADP-ribose (cADPR), a second messenger for glucose-induced insulin secretion. (UniProt, P28907)
Open in Phaseline: the race on CD38, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Mayo Clinic | BCG Solution Glucagon-like peptide 1 receptor agonist | GLP1R, Ion channels, CD38, OPRM1, PDCD1, CD274 | Phase 4 | Pain, Postoperative; Limb Pain, Phantom; Healthy; Respiratory Function Loss … | Nov 2026 |
| Sanofi | H5 Flu IMP 1 Rho-associated protein kinase 2 inhibitor; Rho-associated protein kinase inhibitor | ROCK2, ROCK1, TNFSF4, CD38, IL4R | Phase 4 | RSV Immunization; Diabetes Mellitus, Type 1; Asthma; Dermatitis Atopic … | Dec 2026 |
| Johnson & Johnson (Janssen) | Daratumumab Lymphocyte differentiation antigen CD38 inhibitor | CD38 | Phase 3 | Multiple Myeloma; Amyloidosis; Hemophilia A With Inhibitor; Microvascular Inflammation - MVI in Kindey Transplant Recipients … | Nov 2026 |
| Biogen | Felzartamab Lymphocyte differentiation antigen CD38 inhibitor | CD38 | Phase 3 | Antibody-mediated Rejection; Immunoglobulin A Nephropathy (IgAN); Primary Membranous Nephropathy; Graves' Disease … | Dec 2026 |
| Sinocelltech | SCTC21C anti-CD38 monoclonal antibody | CD38 | Phase 3 | Multiple Myeloma (MM); Amyloidosis; Relapsed or Refractory Hematologic Malignancies | Feb 2027 |
| Celltrion | CT-P44 anti-CD38 monoclonal antibody | CD38 | Phase 3 | Refractory or Relapsed Multiple Myeloma | Mar 2027 |
| Takeda | Mezagitamab (TAK-079) Lymphocyte differentiation antigen CD38 binding agent | CD38 | Phase 3 | Immune Thrombocytopenic Purpura (ITP); Kidney Disease; Antibody-Mediated Rejection (AMR) | Mar 2028 |
| EMN Trial Office S.r.l. Impresa Sociale | Isatuximab-dexamethasone anti-CD38 monoclonal antibody combined with corticosteroid | CD38 | Phase 2 | Relapsed Multiple Myeloma | Mar 2027 |
| Mao Jianhua | SG301 Anti-CD38 monoclonal antibody | CD38 | Phase 2 | Nephrotic Syndrome in Children | Jul 2028 |
| Institute of Hematology & Blood Diseases Hospital, China | Anti-CD38 antibody CD38-targeting monoclonal antibody | CD38 | Phase 2 | Immune Thrombocytopenia | Dec 2030 |
| CASI pharmaceuticals | CID-103 anti-CD38 monoclonal antibody | CD38 | Phase 1 | Chronic Immune Thrombocytopenia; Antibody Mediated Rejection | Dec 2026 |
| Zhejiang ACEA Pharmaceutical | STI-6129 anti-CD38 antibody-drug conjugate with duostatin tubulin inhibitor | CD38 | Phase 1 | Relapsed or Refractory Multiple Myeloma | Dec 2026 |
| GSK | Isatuximab Lymphocyte differentiation antigen CD38 inhibitor | CD38 | Phase 1 | Multiple Myeloma; Newly Diagnosed Multiple Myeloma; Relapsed Refractory Multiple Myeloma (RRMM); Recurrent Multiple Myeloma … | Mar 2027 |
| Masonic Cancer Center, University of Minnesota | FT536 Allogeneic NK cell therapy with CD38 knockout and MICA/B chimeric antigen receptor express | CD38 | Phase 1 | Gynecologic Cancer; Astrocytoma | Jun 2027 |
Multiple Myeloma (60) Immune Thrombocytopenia (7) Plasma Cell Myeloma (6) Recurrent Multiple Myeloma (5) Dermatitis Atopic (5) Newly Diagnosed Multiple Myeloma (4) Colitis Ulcerative (4) AL Amyloidosis (3) T-cell Acute Lymphoblastic Leukemia (3) Recurrent Plasma Cell Myeloma (3) Multiple Myeloma (MM) (3) Acute Lymphoblastic Leukemia (3)
antibody (6), protein or peptide (4), mixed (2), small molecule (2)
Takeda (1) Johnson & Johnson (Janssen) (1) Zhejiang ACEA Pharmaceutical (1) Biogen (1) Masonic Cancer Center, University of Minnesota (1) CASI pharmaceuticals (1) Sanofi (1) Celltrion (1) Mayo Clinic (1) GSK (1) Sinocelltech (1) Mao Jianhua (1) Institute of Hematology & Blood Diseases Hospital, China (1) EMN Trial Office S.r.l. Impresa Sociale (1)
ROCK2 (1) ROCK1 (1) TNFSF4 (1) IL4R (1) GLP1R (1) Ion channels (1) OPRM1 (1) PDCD1 (1) CD274 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.